Daily Roundup

WHC.ASX MND.ASX TLX.ASX SEQ.ASX LDX.ASX

Whitehaven Secures US$600 Million Syndicated Facility

Whitehaven Coal has bolstered its financial position with the securing of a new US$600 million syndicated facility. The facility, which includes a US$475 million term loan and a US$125 million revolving credit, will enhance the company's liquidity, extend its debt maturity profile, and reduce its funding costs.

This new facility reflects the lenders' confidence in Whitehaven's strong credit profile and disciplined financial management. The additional flexibility provided by the facility will support the company's operations and capital management objectives as it continues to execute its long-term strategy.

Monadelphous Wins $145M in New Contracts

Engineering company Monadelphous Group Limited has announced a slew of new contract wins and extensions in the resources sector, valued at approximately $145 million in aggregate. The company has secured a contract with Rio Tinto for a sustaining capital project in the Pilbara region, as well as two-year extensions to its existing maintenance contracts with BHP and Queensland Alumina.

Monadelphous has also been awarded a contract with Harmony Gold for the construction of a Cyclone Dewatering Plant and associated pipeline at the Hidden Valley Gold Mine in Papua New Guinea. These new projects and contract extensions demonstrate the company's continued success in securing work across the resources industry.

Telix Pharmaceuticals' Glioma Imaging Agent Accepted by FDA

Telix Pharmaceuticals has received some positive news from the U.S. Food and Drug Administration (FDA). The agency has accepted the company's resubmitted New Drug Application for TLX101-Px (Pixclara), an investigational PET agent for the imaging of glioma (brain cancer).

TLX101-Px has been granted Orphan Drug and Fast Track designations by the FDA, and its approval will help address a significant unmet medical need for the characterization of recurrent or progressive glioma in both adult and pediatric patients. The FDA has set a PDUFA goal date of September 11, 2026 for the review of the application.

Sequoia Provides Update on InterPrac Disposal

Sequoia Financial Group Ltd has provided an update on the proposed disposal of its subsidiary, InterPrac Financial Planning Pty Ltd, to Conquest Investment Partners Pty Ltd. The company has confirmed that the Australian Securities and Investments Commission (ASIC) has commenced court proceedings to appoint a receiver over certain property of InterPrac, namely the guarantees in the ASIC cross deed of guarantee.

Sequoia believes ASIC's concerns about the sale are unfounded, as InterPrac will remain a party to the ASIC Deed of Cross Guarantee immediately following the sale. The company continues to engage with the ASX regarding whether shareholder approval is required for the transaction and remains committed to progressing the sale in an orderly and transparent manner.

Lumos Diagnostics Secures CLIA Waiver and Announces Placement

Lumos Diagnostics Holdings Limited has received some positive news from the FDA. The agency has granted a Clinical Laboratory Improvement Amendments (CLIA) waiver for the company's flagship point-of-care test, FebriDx, following its earlier 510(k) clearance.

The announcement of the CLIA waiver grant has triggered a $20 million institutional placement by Lumos, which was substantially oversubscribed. The company plans to use the proceeds to fund the commercialization of FebriDx and other growth initiatives.

In a separate announcement, Lumos has also revealed a prospectus offering, including a share purchase plan and placement options, to raise up to A$2 million before costs. This additional capital will further support the company's growth plans.